0000899243-22-003172.txt : 20220125
0000899243-22-003172.hdr.sgml : 20220125
20220125172056
ACCESSION NUMBER: 0000899243-22-003172
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220121
FILED AS OF DATE: 20220125
DATE AS OF CHANGE: 20220125
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Buell Jennifer
CENTRAL INDEX KEY: 0001711184
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40908
FILM NUMBER: 22554805
BUSINESS ADDRESS:
BUSINESS PHONE: 781-674-4400
MAIL ADDRESS:
STREET 1: 3 FORBES ROAD
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MiNK Therapeutics, Inc.
CENTRAL INDEX KEY: 0001840229
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 149 FIFTH AVENUE
STREET 2: SUITE 500
CITY: NEW YORK
STATE: NY
ZIP: 10010
BUSINESS PHONE: 212-994-8250
MAIL ADDRESS:
STREET 1: 149 FIFTH AVENUE
STREET 2: SUITE 500
CITY: NEW YORK
STATE: NY
ZIP: 10010
FORMER COMPANY:
FORMER CONFORMED NAME: AgenTus Therapeutics, Inc.
DATE OF NAME CHANGE: 20210112
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-01-21
0
0001840229
MiNK Therapeutics, Inc.
INKT
0001711184
Buell Jennifer
149 FIFTH AVENUE, SUITE 500
NEW YORK
NY
10010
1
1
0
0
See Remarks
Stock Option (Right to Buy)
3.12
2022-01-21
4
A
0
679800
0.00
A
2032-01-21
Common Stock
679800
679800
D
Represents an option to purchase shares of the common stock, which vests as to 35% of the underlying shares on January 21, 2025 and as to the remaining 65% of the underlying shares on January 21, 2026; provided that the Reporting Person maintains a business relationship with the Issuer through each such vesting date.
President, Chief Executive Officer
By: /s/ Christine Klaskin, attorney-in-fact
2022-01-25